Nobelpharma
NMF Kayabacho Building, 1-17-24, Shinkawa, Chuo-ku, Tokyo, 104-0033, Japan
Overview
Nobelpharma was founded in 2003, and in 2008 we obtained our first marketing approval for an ethical drug, NOBELZIN®. We now have marketing approvals for and sell 18 new drugs and one new medical device. In the pharmaceuticals industry, there are no companies of similar scale and age launching as many new drugs as we have. It is the pursuit of our unique product planning and research and development that has led to this achievement. We engage in the projects of "drugs and medical devices for unmet medical needs" which are critical but neglected. We chose not to carry out the time-consuming and costly basic researches. Instead, we conduct license negotiations and research activities focusing on patient needs and select the best possible candidates (new drug candidates) from outside our company. This is because we want to deliver the drugs and medical devices for unmet medical needs to the medical front as quickly as possible, for the benefit of the patients. Unique management strategy for
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 1
Sector focus
- Biotechnology
- Medical Device
- Pharmaceutical
Investment portfolio
- VLP Therapeutics
Participated · Series A · Dec 2021
VLP Therapeutics (VLPT) develops cancer treatment vaccines and prophylactic vaccines against infectious diseases such as malaria and dengue using its proprietary VLP platform. The company is advancing multiple R&D programs with the stated goal of moving into clinical trials as soon as possible. VLPT was co-founded in 2013 by Wataru Akahata, Ryuji Ueno, and Sachiko Kuno and is led by CEO Wataru Akahata. The additional capital is intended to accelerate both cancer and infectious‑disease vaccine programs and broaden R&D efforts. Financially, the company recently secured a $21M Series A-1 and previously raised $16M in a Series A in March 2021. VLP Therapeutics is a Gaithersburg, Md.–based biotech company developing a cancer treatment vaccine and prophylactic vaccines against malaria, dengue and COVID-19 using proprietary platform technologies. The company was co‑founded in 2013 by Drs. Wataru Akahata, Ryuji Ueno and Sachiko Kuno. It focuses on research and development of vaccine candidates built on virus‑like particle (VLP) technologies. In March 2021 VLP Therapeutics completed a Series A financing totaling $16m. The company intends to use the funds to advance R&D and move its cancer treatment vaccine into clinical trials at the earliest date possible. No operating metrics were disclosed in the article.
Team
Hitoshi Shiomura
Founder, President, and CEO